Research output per year
Research output per year
Search results
-
2024
A new Simple Endoscopic Score for Ulcerative Colitis – the SES-UC
Bergqvist, V., Gedeon, P., Hertervig, E. & Marsal, J., 2024 Dec 13, In: Frontiers in Gastroenterology. 3, 1468394.Research output: Contribution to journal › Article › peer-review
Open Access -
Optimization of tools for monitoring, evaluating, and treating inflammatory conditions of the bowel
Bergqvist, V., 2024, Lund: Lund University, Faculty of Medicine. 90 p.Research output: Thesis › Doctoral Thesis (compilation)
Open AccessFile33 Downloads (Pure) -
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
SWIBREG, 2024, In: Digestive Diseases and Sciences. 69, 6, p. 2175-2183Research output: Contribution to journal › Article › peer-review
Open Access -
2022
Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply
Bergqvist, V., Holmgren, J., Klintman, D. & Marsal, J., 2022 Jun 24, In: Alimentary Pharmacology and Therapeutics.Research output: Contribution to journal › Debate/Note/Editorial
Open Access -
Letter: to switch or not to switch, that is the question—author's reply
Bergqvist, V., Holmgren, J., Klintman, D. & Marsal, J., 2022, In: Alimentary Pharmacology and Therapeutics. 56, 5, p. 922-923Research output: Contribution to journal › Letter
Open Access -
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
Bergqvist, V., Holmgren, J., Klintman, D. & Marsal, J., 2022, In: Alimentary pharmacology & therapeutics. 55, 11, p. 1389-1401Research output: Contribution to journal › Article › peer-review
Open Access -
2018
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
Bergqvist, V., Kadivar, M., Molin, D., Angelison, L., Hammarlund, P., Olin, M., Torp, J., Grip, O., Nilson, S., Hertervig, E., Lillienau, J. & Marsal, J., 2018, In: Therapeutic Advances in Gastroenterology. 11, 175628481880124.Research output: Contribution to journal › Article › peer-review
Open Access -
2017
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A. & Marsal, J., 2017, In: Cancer Immunology and Immunotherapy. 66, 5, p. 581-592Research output: Contribution to journal › Article › peer-review
Open Access